MNPR MONOPAR THERAPEUTICS Product Launches 8-K Filing 2023 - Discontinuation of Validive Phase 2b/3 VOICE trial Monopar Therapeutics announced the discontinuation of its Validive Phase 2b/3 VOICE trial for the prevention of severe oral mucositis, and will focus on other clinical trials and programs.Get access to all SEC 8-K filings of the MONOPAR THERAPEUTICS